Shomerosh

Company Overview

Snapshot

Founded in September 2016, Shomerosh operates with 1–10 employees and has raised $200K across one funding round. The company holds a patent for its technology, which focuses on early detection of Alzheimer's disease.

Business overview

Shomerosh develops a free, noninvasive, and user-friendly mobile application designed to detect Alzheimer's disease at the preclinical stage. Its core technology utilizes a novel personalized cognitive task, sensitive to the very early stages of the disease, to provide a predictive model. The company serves the healthcare industry, focusing on digital healthcare, and operates within sectors such as digital medical diagnostics, artificial intelligence, and machine learning, targeting patients and providers.

Company Intelligence Q&A

What is Shomerosh's primary focus?

Shomerosh is focused on developing an app for detecting preclinical Alzheimer's disease, aiming to identify the condition at a stage where neural pathology may still be reversible.

When was Shomerosh founded?

Shomerosh was founded in September 2016.

What is the key technology behind Shomerosh's product?

The company's key technology is a novel personalized cognitive task that can be completed from home, forming the basis of its predictive model for early Alzheimer's detection.

What is the current status of Shomerosh?

Shomerosh is currently non-active, having ceased operations in August 2024.

What is the product stage of Shomerosh's offerings?

Shomerosh's product, Clara, is currently in the Alpha stage, indicating it is an early version of the product for internal testing and evaluation.